Menopause
The Irish start-up on a mission to help women navigate menopause
identifyHer’s medical device will be able to monitor menopausal symptoms and help clinicians give a better diagnostic

Disease prevention means data. Heidi Davis, co-founder of the Irish start-up identifyHer, tells FemTech World why a medical wearable device is essential in understanding menopause and predicting future disease.
The effect of menopausal symptoms on women’s future health is rarely talked about.
In the UK and Ireland, 3.7 million women are experiencing symptoms that negatively affect their lives during perimenopause and menopause and untreated, such symptoms can lead to chronic diseases.
“Understanding menopause is extremely important to assess the future risks of disease,” says Heidi Davis, co-founder of identifyHer. The Irish digital health company focuses on predictive health services for women going through menopause, guiding personalised management of menopausal symptoms.
“When we started, we realised that nobody knew anything about menopause and that there was no real objective data to understand this life stage,” the co-founder explains. “So, we looked at a range of symptoms that we believed we could capture with a wearable sensor that could identify those physiological changes.
“We collected data from women who were going through menopausal symptoms and we understood that they are the ones who are looking for this information, who need this information and who are desperate to understand what’s going on.”
Along with the American manufacturing company, Analog Devices, the identifyHer team is developing a medical device that uses AI-enabled technology to capture physiological signals and personalise the management of menopausal symptoms to reduce the risk of disease in the future.
“The symptoms women experience [during perimenopause and menopause] can overlap with other symptoms that happen in daily life,” Davis points out.
“For that reason, clinicians find it hard to diagnose and give treatment because they don’t have diagnostic tests that can give a clear image. So, our mission is to help them differentiate those symptoms and provide objective data.”
The identifyHer tracker, which can be used from perimenopause onwards, sits under the breast and is activated by an app. The wearer goes about their business as normal and they will get daily, weekly, and monthly reports on their menopausal symptoms and lifestyle data.
The woman will wear the sensor for three months to track her symptoms and the data collected during that time will be used to initiate or evaluate the treatment she is already on.
The device will not only save clinicians time, but it will also offer them a better diagnostic tool and help them improve and change the treatment accordingly.
“Managing those symptoms correctly can actually set women up for a better future post-menopause because the severity and the frequency of the symptoms themselves are indicators of future risk of disease,” Davis adds.
“Women who seek medical help will be offered our solution and get remote monitoring of their symptoms while clinicians can use it for diagnosis and treatment.”
The device will be regulated both for cybersecurity and data protection and it will first launch in the UK and Ireland, followed by the EU and the US. The company will be working with health insurance companies on a paying claim policy and hopes that with time, the tracker will be integrated into the national healthcare systems.
“It’s been great to be working in women’s health,” the entrepreneur tells me. “It has been challenging, but the overall experience was good.
“We are hoping to close a round of €2.2 million by the end of this year and our aim is to become the gold standard in clinics to diagnose and help women get the right treatment. So far, we’ve had some good conversations and we are moving forward.”
Before we wrap up our Zoom call, I ask Heidi what is her biggest achievement since establishing identifyHer.
“Building the team. We wouldn’t be where we are now, if it wasn’t for the people that have helped us along the journey. It took us a long time to find them, but we knew they were the right people straight away.
“I hope we can continue growing it with as good people as we have now.”
For more info, visit identifyher.ai.
News
Women still being failed when they reach menopause, experts say
Hormonal health
Sweden eyes domestic production of oestrogen patches amid menopause treatment shortage
Menopause
Post-menopause memory decline linked to loss of oestrogen production in brain tissue – study

Oestrogen loss in brain tissue may help explain memory decline after menopause and women’s higher Alzheimer’s risk, a preclinical study suggests.
The findings suggest females may be especially sensitive to the loss of brain oestrogen in old age.
Scientists said the work could point to future treatments focused on restoring the brain’s supportive environment before memory loss develops.
Dr Hong Zhao, research professor of obstetrics and gynaecology in the division of reproductive science in medicine at Northwestern University Feinberg School of Medicine, said: “This study tells us that females, but not males, may be uniquely sensitive to loss of brain oestrogen at old age, potentially contributing to an increased risk of Alzheimer’s disease.”
Researchers at Northwestern University studied young and old male and female mice, with and without loss of brain oestrogen.
The study focused on the extracellular matrix, or ECM, a network of molecules in the space between brain cells. It helps support communication between cells and is important for memory, brain development and brain health. The ECM makes up nearly 20 per cent of the brain’s volume.
The ECM is especially abundant in the hippocampus, a part of the brain involved in learning and memory.
Scientists found that oestrogen loss, ageing and female sex were closely linked to changes in the ECM. The study is the first to examine oestrogen loss in the ECM.
The findings may help explain why women are at higher risk of Alzheimer’s disease, although the research was carried out in mice and further work is needed to understand whether the same mechanisms apply in humans.
Nearly two-thirds of people with Alzheimer’s disease in the US are women, but the reasons for this higher risk remain unclear.
Scientists have long suggested that falling oestrogen levels after menopause may reduce the brain’s natural protection against memory loss and neurodegeneration. Neurodegeneration means the gradual damage or loss of nerve cells in the brain.
Dr Serdar Bulun, chair of the department of obstetrics and gynaecology at Feinberg and a Northwestern Medicine physician, said: “We have provided some of the most compelling evidence that oestrogen is so important for memory function and other mood functions in the female brain.
“This should motivate clinicians to be more aware of the essential role of oestrogen for women’s brains, because once memory is gone, it’s gone.”
Before menopause, the ovaries are the main source of oestrogen in women. After menopause, oestrogen levels drop sharply, and only small amounts are produced in other parts of the body, including the brain, fat tissue, bone, muscle, blood vessels and breast tissue.
In mice, oestrogen is produced locally in the brain and gonadal fat in males, whereas in females it is produced mainly in the brain.
Research has shown that women with Alzheimer’s disease may have even lower oestrogen levels in the brain than women without the disease. The study further supports that.
The researchers used genetically engineered mouse models that lacked aromatase, an enzyme needed to produce oestrogen, either throughout the whole body or only in the brain.
They examined how the loss of oestrogen affected memory, behaviour and social function in male and female mice at young and old ages.
They also analysed changes in gene expression across the entire genome in the hippocampus in mice with brain-specific oestrogen loss at young and old ages in both sexes.
The authors said the findings suggest the ECM could become a target for future treatments.
Current Alzheimer’s treatments such as lecanemab and donanemab are designed to remove amyloid, an abnormal protein build-up in the brain that is one of the main signs of the disease.
However, researchers said it is still unclear how much these treatments help to slow memory loss or improve everyday functioning. Some studies suggest small benefits, while others show little meaningful improvement.
The study suggests a different approach could focus on restoring the brain’s supportive environment to help protect memory.
Zhao said: “Our findings will hopefully motivate future studies to better understand how this matrix is altered in postmenopausal women, and how it could potentially induce susceptibility to Alzheimer’s disease.”
Hormone replacement therapy, or HRT, has also been studied as a possible way to protect women from Alzheimer’s disease by restoring oestrogen levels.
However, clinical studies have produced mixed results, with some suggesting benefits for memory and cognitive function while others show little benefit or possible harm.
Zhao said differences may depend on the type of hormone treatment used, the age at which it begins and differences in study design.
She said: “More research is needed to understand how oestrogen affects the female brain and why oestrogen loss increases AD risk in women.
“Understanding these mechanisms could help researchers develop safer and more effective HRT strategies to prevent or slow the progression of AD in women.”
Motherhood4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Menopause5 days agoPerimenopause misinformation ‘putting women at risk’
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’
















3 Comments